Xarelto Evidence in Real Life of Patients Preference and Satisfaction Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms X-PRESS
- Sponsors Bayer
- 11 Oct 2017 Planned primary completion date changed from 31 Dec 2017 to 30 Jan 2018.
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2017 Planned End Date changed from 1 Mar 2018 to 31 Mar 2018.